Glaucoma is a group of diseases that can damage the optic nerve of the eye and lead to vision loss. Elevated intraocular pressure is the main risk factor. Drug therapy remains an important component of glaucoma treatment. Therefore, Ace Therapeutics is dedicated to discovering possible targets in glaucoma, developing and designing new compounds, and evaluating drug therapies, and we provide researchers and pharmaceutical companies with strategies for molecular drug development in glaucoma.
Services for Small Molecule Drug Development for Glaucoma
Rho kinase (ROCK) inhibitors have been identified as glaucoma therapeutic agents that can reduce IOP in glaucoma. ROCK inhibitors target TM tissue and increase AH drainage to slow damage to the optic nerve. For ROCK inhibitors, we provide development services for scientists and pharmaceutical companies working to design and develop novel molecular scaffolds to improve drug efficacy and stability.
The current therapeutic goal of the main ocular drugs is to lower IOP. One of the main treatment options is carbonic anhydrase inhibitors (CAIs), which lower IOP in patients with glaucoma by decreasing the rate of bicarbonate formation and thus atrial fluid secretion. We are dedicated to uncovering new targets and actions of CAIs, helping researchers to design novel and selective inhibitors.
Extensive studies have demonstrated that adenosine receptors (ARs) may serve as neuroprotective therapeutic targets. And AR may play a role in the prevention of RGC loss in glaucoma. The use of adenosine receptor-related drugs to protect the RGC in glaucomatous eyes may be a very promising glaucoma therapy. We hope that new developments in adrenergic modulators may lead to more options for glaucoma drug therapy.
As science advances, new targets and therapeutic diseases emerge, but adrenergic modulators continue to play an important role in the treatment of glaucoma. These include mainly α-adrenergic agonists and β-adrenergic antagonists. We provide resources and research to support the development of drugs with specific receptor effects and demonstrate their efficacy and safety.
Studies have demonstrated the great potential of prostaglandin (PG) receptors to control IOP. Current first-line drugs for the treatment of glaucoma are PG analogs, which stimulate intraocular PG receptors and lower IOP by primarily increasing aqueous outflow. We offer research services for the detailed exploration of different PG receptors, the development of drugs targeting prostaglandin receptors for glaucoma treatment.
Nitric oxide (NO) is an endogenous gas signaling molecule that inhibits aqueous production and increases aqueous outflow from the atrium, thereby reducing IOP. Therefore, NO donating anti-glaucoma drugs have a broad research potential. For glaucoma treatment, we provide services for the development of NO-mediated next-generation anti-glaucoma drugs.
Collaborate with Us
We aim to develop different novel drugs for the treatment of glaucoma and to explore their mechanisms of action. By targeting the trabecular meshwork, uveosclera, optic nerve and other tissues to regulate IOP, atrial aqueous production and outflow as therapeutic targets. We offer the development of novel drug formulations derived from various molecular drugs such as Rho kinase inhibitors, prostaglandin analogs, carbonic anhydrase inhibitors, beta-blockers, alpha agonists, nitric oxide donors, etc.
Collaborate with us and contact us to facilitate the expansion and customization of glaucoma treatment options.